Aspire Biopharma, PowerUp Acquisition complete business combination
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2025
0mins
Should l Buy ?
Business Combination Completion: Aspire Biopharma and PowerUp Acquisition Corp. have successfully completed their business combination, which was approved by stockholders on January 31, 2025, and closed on February 17, 2025.
Trading Information and Future Plans: Starting February 20, Aspire Biopharma's shares will trade on Nasdaq under the symbols "ASBP" and "ASBPW," with expectations of improved capital access, product development, and potential FDA fast-track approval for their fast-absorbing aspirin aimed at cardiac incidents.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
